IO Frontiers World 2019


Jerrod Denham

Jerrod Denham

Principal & Senior Consultant, Dark Horse Consulting, Inc
After training at UCLA in Molecular Biology and Physiological Sciences, Jerrod Denham has worked in the cell therapy industry for 18 years with increasing roles of responsibility.  At Geron Corporation, he was involved with research, process engineering, manufacturing sciences, pilot production, early stage manufacturing and dose administration in support of the world’s first IND for a human embryonic stem cell-derived product and its subsequent testing in a human clinical trial. In his latest role of Senior Manager, Process Engineering, he also led the technology transfer of both autologous and allogeneic product dose preparation procedures at 13 US clinical sites.

As Associate Director, Process Development Engineering at ViaCyte, Inc., Mr. Denham was responsible for process verification, technology transfer and pilot production in support the world’s first IND for a human embryonic stem cell-derived combination product (cells + encapsulation device) for type 1 diabetes mellitus which was then tested in a Phase I clinical trial.

Most recently, Mr. Denham served as Director, Process Engineering and Manufacturing Sciences at Stem Cells Inc.  Here he led process development activities in support of multiple US FDA CMC amendments, which allowed the use of human central nervous stem cells in Phase 2 clinical trials for two clinical indications.

Jerrod is now a Principal and Senior Consultant at Dark Horse Consulting, where he focuses on upstream and downstream process engineering for cell and gene therapy products.
  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy